IndustryCompany release

Medline raises 2026 organic sales outlook after $7.9bn third quarter, approves $1bn buyback

🇺🇸 Medline Inc. (MDLN) · Wed 04 Nov 2026

The US medical supplies group reported third-quarter net income of $318 million, helped by tariff refunds, and lifted its full-year organic sales growth guidance while holding its EBITDA outlook.

Medline Inc. (Nasdaq: MDLN) reported results for the quarter ended 26 September 2026 on 4 November, posting net sales of $7.9 billion and net income of $318 million. The company's headline described sales growth of 10.4%.

Net income was helped by refunds of tariffs imposed under the International Emergency Economic Powers Act (IEEPA), following the US Supreme Court's February 2026 ruling on the matter.

Medline raised its 2026 organic sales growth guidance to a range of 10.0% to 10.5%. It left its Adjusted EBITDA outlook unchanged at $3.3 billion to $3.4 billion.

On capital allocation, the company authorised a $1 billion share repurchase programme and prepaid $750 million of its term loan debt. The material provided did not include further detail on timing or the structure of either measure.

What it means for your team

  • Market-access and procurement teams can read the raised organic growth guidance as a sign of continued demand for Medline's products and services, though the available material gives no segment detail.
  • Supply-chain and finance teams should note that IEEPA tariff refunds contributed to the quarter's profit, following the Supreme Court's February 2026 ruling.
  • The unchanged Adjusted EBITDA outlook suggests the company has not changed its profitability expectations for the year.

Company's press release (SEC filing): Medline Inc. ↗

Article written by VigiEye from the official source (Medline Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →